Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Magle Group successfully places senior secured bonds of SEK 350 million

Magle Chemoswed Holding
Download the release

Magle Chemoswed Holding AB (publ) ("Magle Group") has today successfully placed senior secured bonds in an amount of SEK 350 million with a tenor of three years (the "Bonds"). The Bonds will carry floating rate interest of STIBOR 3m plus 6.50 per cent. per annum and will be issued at 97 per cent. of par value. The issue date for the Bonds is expected to be on or about 4 July 2025.

The net proceeds from the Bonds will be used to refinance existing debt and for general corporate purposes, including investments, acquisitions and capital expenditure.
 
The Bonds will be listed on a regulated market within twelve months and Nasdaq Transfer Market within 60 days (with the intention to list within 30 days).
 
Pareto Securities acted as Sole Bookrunner, Advokatfirman Schjødt acted as legal advisor to Magle Group, and Roschier Advokatbyrå acted as legal advisor to Pareto Securities in connection with the bond issue. Vator Securities acted as financial advisor to Magle Group.

Contacts Justin & Aaron


Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

Aaron Wong, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us


The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-24 17:20 CEST.

Attachments


Magle Group successfully places senior secured bonds of SEK 350 million

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.